Li Cuilin, Zou Hecun, Wang Zhifei, Tang Xinyue, Fan Xitang, Zhang Ke, Liu Jianqiu, Li Zhi
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Institute of Clinical Pharmacology, Central South University and Hunan Key Laboratory of Pharmacogenetics, Changsha, China.
Drug Des Devel Ther. 2018 May 22;12:1363-1371. doi: 10.2147/DDDT.S161602. eCollection 2018.
BACKGROUND/AIM: Repressor element silencing transcription factor () is a transcription repressor, expressed in several malignancies. This study aims to evaluate the prognostic values of and its splicing variant in glioma, and investigate the potential correlation between and .
and expression values were evaluated by qRT-PCR in 89 patients with gliomas and 10 with normal brain tissues.
Upregulation of was related to higher World Health Organization (WHO) grade, larger tumor size, higher ki67, and higher p53 positive rate. After radiotherapy+temozolomide (RT+TMZ) treatment, low expression patients could get better therapeutic efficacy (=0.031). The positive rate of expression was only 13.5% in glioma tissues, and expression was not associated with clinical characteristics and expression in this study.
was a prognostic factor in glioma, while was not. expression can be a predictor in evaluating the survival outcome of gliomas patients treated with RT+TMZ after surgery.
背景/目的：阻遏元件沉默转录因子（）是一种转录抑制因子，在多种恶性肿瘤中表达。本研究旨在评估和其剪接变体在胶质瘤中的预后价值，并探讨与之间的潜在相关性。
通过qRT-PCR评估89例胶质瘤患者和10例正常脑组织患者中的和表达值。
的上调与世界卫生组织（WHO）分级更高、肿瘤体积更大、ki67更高以及p53阳性率更高有关。放疗+替莫唑胺（RT+TMZ）治疗后，低表达患者可获得更好的治疗效果（=0.031）。在胶质瘤组织中表达的阳性率仅为13.5%，且在本研究中，的表达与临床特征及的表达无关。
是胶质瘤的一个预后因素，而不是。的表达可作为评估手术后接受RT+TMZ治疗的胶质瘤患者生存结果的一个预测指标。
